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Effect of N-acetylcysteine for prevention of contrast nephropathy in
patients with moderate to severe renal insufficiency: A randomized trial
Fung JWH, Szeto CC, Chan WWM, et al. Am J Kidney Dis 2004;43:801–8.
Conclusion: Oral N-acetylcysteine (NAC) had no effect on prevention
of contrast nephropathy in patients with moderate-to-severe renal insuffi-
ciency undergoing coronary angiography or coronary interventions.
Summary: N-acetylcysteine is used as an antioxidant to prevent con-
trast nephropathy in patients undergoing contrast studies. The authors point
out conflicting results in randomized trials evaluating the efficacy of this
approach. They performed a prospective, open-label, randomized con-
trolled trial, in which 91 consecutive patients with a serum creatinine of
1.69–4.52 mg/dL who were undergoing coronary procedures were ran-
domly assigned to be administered either oral NAC, 400 mg 3 times daily
the day before and the day of the contrast procedure, or no drug (control
group). Serum creatinine was measured before and 48 hours after contrast
exposure. The primary end point was development of contrast nephropathy
defined as an increase in serum creatinine of 0.5 mg/dL or greater, or a
reduction in estimated glomerular filtration rate (GFR) of 25% or greater of
baseline value 48 hours after exposure to contrast.
There were 46 patients randomized to the NAC group and 46 controls.
The groups did not differ in baseline characteristics or mean volume of
contrast administered. Six patients (13.3%) in the control group and 8
patients (17.4%) in the NAC group developed contrast nephropathy (P 
.8). Serum creatinine levels increased from 2.27  0.54 to 2.45  0.65
mg/dL in the NAC group, and from 2.37 0.61 to 2.40 0.70 mg/dL in
the control group (P  .6). The increase in serum creatinine levels also did
not differ between the 2 groups (P  .7). Estimated GFR decreased from
30.3  8.4 to 28.1  8.4 mL/min (P  .01) in the NAC group and from
28.4  8.6 to 27.5  8.8 mL/min (P  .3) in the control group. The
decline in estimated GFR between the 2 groups was not significant (P .7).
Comment: In Table 2 of this article the authors summarize 15 previous
reports evaluating the effect of NAC on prevention of contrast nephropathy
in patients with renal insufficiency. Only 5 of the 15 reports indicate a benefit
in the use of NAC to prevent contrast nephropathy. The largest trial
evaluating NAC and the prevention of contrast nephropathy showed a
positive result, but the patients in that study had relatively mild renal
impairment. The potential benefit of NAC in preventing contrast nephrop-
athy in patients with more significant degrees of renal impairment remains
unproven.
Prevention of contrast-induced nephropathy with sodium bicarbonate
in a randomized controlled trial
Merten GJ, Burgess WP, Gray LP, et al. JAMA 2004; 291:2328–34.
Conclusion: Prior to contrast exposure, hydration with sodium bicar-
bonate is more effective than hydration with sodium chloride for prevention
of contrast-induced renal failure.
Summary: This was a prospective, single-center randomized trial of
119 patients with stable serum creatinine levels of at least 1.1 mg/dL.
Patients were randomized to receive a 154-mEq/L infusion of either
sodium chloride (n  59) or sodium bicarbonate (n  60) before and after
intravenous contrast administration (370 mg iodine/mL). Creatinine levels
were measured at baseline and at 1 and 2 days after contrast administration.
Either sodium bicarbonate or sodium chloride (154 mEq/L) was adminis-
tered as a bolus of 3 mL/kg per hour for 1 hour prior to contrast adminis-
tration. This was followed by an infusion of 1 mL/kg per hour for 6 hours
after completion of the procedure. Contrast-induced nephropathy was
defined as an increase of 25% or more in serum creatinine within 2 days of
contrast administration.
The 2 groups did not differ with respect to sex, prevalence of diabetes
mellitus, ethnicity, or contrast volume. Baseline serum creatinine was slightly
higher, but not statistically different, in patients receiving sodium bicarbon-
ate treatment than sodium chloride treatment (mean [SD], 1.71 [0.42]
mg/dL) and 1.89 [0.69] mg/dL; P .09). Contrast-induced nephropathy
occurred in 8 patients (13.6%) treated with sodium chloride but in only 1
(1.7%) of those receiving sodium bicarbonate (difference, 11.9%; 95%
confidence interval, 2.6%-21.2%; P  .02). A follow-up registry of 191
consecutive patients receiving prophylactic sodium bicarbonate and meeting
the same inclusion criteria as the study resulted in 3 cases of contrast-induced
nephropathy (1.6%; 95% confidence interval, 0%-3.4%).
Comment: Animal models suggest pretreatment with sodium bicar-
bonate may be more effective than sodium chloride in prevention of acute
ischemic renal failure. Renal failure from both ischemia and contrast is
postulated to occur at least partially from free-radical injury. The success of
sodium bicarbonate in reducing contrast-induced nephropathy is consistent
with the hypothesis that contrast injury is induced by free radicals. This study
contains persuasive data that sodium bicarbonate, rather than sodium chlo-
ride, should be used to provide pre- and postprocedure hydration in patients
undergoing contrast administration.
A Comparison of albumin and saline for fluid resuscitation in the
intensive care unit
The Safe Study Investigators. N Engl J Med 2004;350:2247–56.
Conclusion: In intensive care unit (ICU) patients, normal saline and
4% albumin for fluid resuscitation result in similar outcomes at 28 days.
Summary: The authors performed a multicenter randomized double-
blind trial to compare the effect of fluid resuscitation with albumin or saline
in a population of ICU patients. Patients 18 years or older who were
admitted to the ICU in 16 academic tertiary hospitals in Australia and New
Zealand were evaluated for participation in the study. Patients undergoing
cardiac surgery, liver transplantation, or treatment of burns were excluded.
Patients were randomly assigned to receive either normal saline or 4%
albumin for fluid resuscitation for the next 28 days. The primary outcome
measure was death from any cause within 28 days of randomization. Sec-
ondary outcome measures were the proportion of patients who had 1, 2, 3,
4, or 5 new organ failures; survival time during the first 28 days; duration of
mechanical ventilation; duration of renal replacement therapy; and duration
of ICU and hospital stay.
Of the 6997 study participants, 3497 were randomized to the albumin
group and 3500 to the saline group. The 2 groups had similar baseline
characteristics. There were 729 deaths in the saline group and 726 deaths in
the albumin-treated patients, P  .87. There were no differences between
the number of patients in each group with single or multiple organ failure,
P .85. There were also no significant differences between the groups in the
number of days spent in the ICU (6.5 6.6 in the albumin group and 6.2
6.2 in the saline group; P .44), total hospital days (15.3 9.6 and 15.6
9.6, respectively: P  .3), days of mechanical ventilation (4.5  6.1 and
4.3  5.7, respectively; P  .74), or days of renal replacement therapy
(0.5  2.3 and 0.4  2.0, respectively; P  .41).
During the first 3 study days patients receiving albumin had signifi-
cantly less fluid administered than those assigned to saline. The overall ratio
of volume of albumin to volume of saline administered during the first 4 days
was 1:1.4. After day 4 there were no difference in the 2 groups in volume of
study fluids administered.
Comment: Because it appears in the New England Journal of Medicine,
this article will likely be widely cited. The data, however, may not apply to
surgical patients undergoing massive resuscitation or to vascular surgical
patients. There is no breakdown of the number of patients undergoing
elective or urgent aortic surgery, or those who required massive amounts of
fluid resuscitation. The study should not be used to justify therapies in
specific subgroups of surgical patients, especially those who require massive
resuscitation.
Aneurysmal hypertension and its relationship to sac thrombus: A
semi-qualitative analysis by experimental fluid mechanics
Chaudhuri A, Ansdeoll E, Grass AG, et al. Eur J Vasc Endovasc Surg
2004;27:305–10.
Conclusion: Intraluminal thrombus in an aortic aneurysm may result
in localized areas of high intraluminal pressure.
Summary: Using a pulsatile flow model, the authors investigated the
effect of aneurysm thrombus and luminal diameter on pressure within the
abdominal aortic aneurysm model lumen and at the sac wall. A latex model
of an abdominal aortic aneurysm was incorporated into a pulsatile flow unit,
using blood pressures settings of 140/100 mm Hg and 130/90 mm Hg
(donated high and low settings, respectively). Pressures in the aneurysm sac
were measured in the absence of thrombus within the sac and were repeated
after a thrombus analog (gelatin) was introduced into the aneurysm model.
Using both pressure settings, luminal pressures and sac wall pressures were
compared with systemic pressure and with each other.
With the aneurysm sac devoid of thrombus, luminal and sac wall
pressures were identical to systemic pressure with high- and low-pressure
settings. With introduction of thrombus, pressure was transmitted in a
monophasic pulsatile fashion, with increases in systolic, diastolic, and mean
pressures at the sac wall compared with luminal pressure (166/142/151
mm Hg vs 164/136/145 mm Hg; P .001) with the high-pressure setting.
In the low-pressure setting readings were 157/133/141 mm Hg at the sac
wall for systolic, diastolic, and mean pressures versus 160/128/138 mm Hg
833
for systolic, diastolic and mean pressures within the lumen (P  .001). Sac
wall pressures were significantly higher than luminal pressures for both high
and low settings (P  .001).
Comment: Arterial pressure waves contribute to wall stress within an
abdominal aortic aneurysm sac. These pressure waves can be modified by
changes in the aortic aneurysm sac and the sac contents. This study, along
with studies from the University of Pittsburgh and Dartmouth, suggest areas
of increased stress on certain points of the aneurysm wall. At some point it
may be possible to map stress points on the wall of an abdominal aortic
aneurysm and to predict likelihood of rupture with greater certainty than is
currently possible with measurement of aneurysm diameter alone.
Hemodynamic effect of intermittent pneumatic compression of the leg
after infrainguinal arterial bypass grafting
Delis KT, Husmann MJ, Szendro G, et al. Br J Surg 2004;91:429–34.
Conclusion: Intermittent pneumatic compression after infrainguinal
bypass grafting improves infrainguinal graft flow velocity.
Summary: This study examined the immediate effects of intermittent
pneumatic compression (IPC) applied to the foot (IPCfoot), the calf (IPC-
calf), and both simultaneously (IPCfootcalf) on the hemodynamics of in-
frainguinal bypass grafts. There were 18 femoral popliteal and 18 femoral
distal autogenous vein grafts included in the study. All limbs had a resting
ankle-brachial pressure index of 0.9 or greater. Graft surveillance and
measurement of graft hemodynamics were conducted at rest and within 5
seconds of IPC in each mode, using duplex imaging. Outcome measures
included peak systolic velocity (PSV), mean velocity (MV), end diastolic
velocity (EDV), pulsatility index (PI), and volume flow in the graft.
All modes of intermittent pneumatic compression enhanced PSV and
volume flow in both femoral popliteal and femoral distal bypass grafts.
IPCfootcalf was the most effective. IPCfootcalf enhanced median PSV, MV,
and volume flow in femoral-popliteal grafts by 49%, 236%, and 182%,
respectively. It attenuated PI by 61%. IPCfootcalf enhanced median PSV,
MV, and median volume flow in femoral distal grafts by 53%, 179%, and
273%, respectively. PI was attenuated by 63%.
Comment: The article is interesting but of little practical significance.
To achieve significant enhancement of graft flow with IPC, the limb must be
dependent and therefore is more subject to postoperative swelling. It is also
unclear whether these devices will increase postoperative discomfort in the
operated extremity. Pedal devices might be contraindicated in patients with
pedal gangrene and calf devices contraindicated in patients with distal calf
wounds. Finally, it is unknown whether the short-term increase in flow
velocities provided by these devices will result in long-term graft patency.
Incidence of chronic thromboembolic pulmonary hypertension after
pulmonary embolism
Pengo B, Lensing WA, Prins MH, Thromboembolic Pulmonary Hyperten-
sion Study Group. New Engl J Med 2004;350:2257–64.
Conclusion: Chronic thromboembolic pulmonary hypertension
(CTPH) is a relatively common long-term serious complication of acute
pulmonary embolism.
Summary: The authors conducted a prospective, long-term study to
assess the incidence of symptomatic CTPH in patients with an acute episode
of pulmonary embolism (PE) but without prior venous thromboembolism
(VTE). Patients who had persistent and unexplained dyspnea during fol-
low-up underwent transthoracic echo and, when supportive findings were
present, ventilation-perfusion lung scanning and pulmonary angiography.
CTPH was diagnosed if systolic and mean pulmonary artery pressures
exceeded 40 and 25 mm Hg, respectively; pulmonary capillary wedge
pressure was normal; and there was angiographic evidence of pulmonary
artery disease.
The authors identified 314 consecutive patients with acute PE. Eighty-
one were excluded because of coexisting conditions potentially responsible
for nonthromboembolic pulmonary hypertension. Overall, 223 patients
were followed. Median follow-up was 94.3 months, and maximum fol-
low-up was 10 years. There were no patients lost to follow-up.
Of the 223 patients, 32 (14.3%) had recurrent episodes of documented
VTE. The incidence of recurrent VTE was 4.9% at 3 months, 8.0% at 1 year,
22.1% at 5 years, and 29.1% at 10 years. Of the 223 patients, 18 died as a
direct consequence of the first PE, with 17 deaths occurring on the first day
and 1 on the second day. In 7 of 223 patients, symptoms developed that
proved to be due to CTPH and in only 2 cases were symptoms preceded by
recurrent PE. The cumulative incidence of symptomatic CTPH was 1% at 6
months, 3.1% at 1 year and 3.8% at 2 years. No cases occurred after 2 years
among patients with more than 2 years of follow-up. Risk of CTPH was
increased by a previous PE (odds ratio [OR], 19.0), younger age (OR,
1.79/decade), a larger perfusion defect (OR, 2.22/decile decrement in
perfusion), and idiopathic PE at presentation (OR, 5.7).
Comment: The article indicates that CTPH is much more common
than previously suspected, with previous articles suggesting an incidence of
0.1% to 0.5% following acute nonfatal PE (New Engl J Med 2001;345:
1465–72). The disease however, is not inevitably associated with symptom-
atic VTE (New Engl J Med 350;22:2236–8) and does not share usual
systemic and coagulation risk factors with VTE. The whitish-yellow fibrotic
organized thromboembolism in a patient with CTPH strongly resembles
chronic venous thrombosis of the extremities. The key to CTPH may lie in
the resolution of the thrombotic process rather than the original embolus.
Prevention of disabling and fatal strokes by successful carotid endar-
terectomy in patients without recent neurologic symptoms: Random-
ised controlled trial
Halliday A, Mansfield A, Marro J, Asymptomatic Carotid Surgery Trial
(ACST) Collaborative Group. Lancet 2004;363:1491–502.
Conclusion: In asymptomatic patients younger than 75 years of age
with 70% carotid stenosis on ultrasound, immediate carotid endarterec-
tomy (CEA) decreases the net 5-year stroke risk from about 12% to about 6%
(including a 3% perioperative stroke and death rate), with half of the 5-year
benefit involving fatal or disabling strokes.
Summary: From 1993 to 2003, 3120 asymptomatic patients with
“substantial carotid narrowing” were randomized equally between immedi-
ate CEA (half receiving CEA by 1 month, 88% by 1 year) and indefinite
deferral of CEA (only 4% per year receiving CEA). Follow-up was for up to
5 years (mean, 3.4 years). Assessment of carotid stenosis was by locally
validated criteria, with results generally rounded to 70%, 80%, or 90%. One
hundred twenty-six hospitals, primarily in Europe, participated in the study.
Surgeons participating in the study were required to submit 50 CEAs and
have a documented stroke and death rate of 6% at 30 days.
The risk of stroke or death within 30 days of CEA was 3.1% (95% CI,
2.3%-4.1%). Combining perioperative events and nonperioperative strokes,
net 5-year risk in immediate CEA patients versus all allocated deferral
patients was 6.4% versus 11.8% for all stroke (net gain, 5.4% [3.0–7.8]); P
.0001), 3.5% versus 6.1% for fatal or disabling stroke (net gain, 2.5%
[0.8–4.3]); P .004), and 2.1% versus 4.2% for fatal strokes(net gain, 2.1%
[0.6–3.6]; P  0.006). Benefits were significant for both men and women;
for those with about 70%, 80%, and 90% carotid artery narrowing on
ultrasound; and for those younger than 65 years of age and those 65–74
years of age.
Comment: This is a later and larger variant of the ACAS trial. The
study indicates benefit for patients with asymptomatic carotid stenosis who
undergo prophylactic CEA. However, the data also indicate that, with good
medical care, patients with high-grade carotid stenosis have an annual stroke
risk of only about 2% without CEA. In addition, morbidity and mortality of
CEA must be low for benefit to be achieved. Like ACAS, the authors found
no stratification of benefit of CEA in patients stratified for increasing carotid
stenosis, perhaps reflecting the variability of ultrasound diagnosis. In con-
trast to ACAS, this study found benefit for CEA for asymptomatic carotid
stenosis in women.
Reduced neuropsychological test performance in asymptomatic carotid
stenosis: The Tromso Study
Mathiesen EB, Waterloo K, Joakimsen O, et al. Neurology 2004; 62:695–
701.
Conclusion: Carotid stenosis is associated with poor neuropsycholog-
ical performance.
Summary: The authors sought to assess the relationship between
asymptomatic carotid stenosis, silent magnetic resonance imaging (MRI)
lesions, and neuropsychological tests performance. The study consisted of
189 subjects with ultrasound-documented carotid stenosis and 221 control
subjects without carotid stenosis. The patients were recruited from a popu-
lation study. People with previous strokes were excluded. Study subjects
were assessed with neuropsychologic tests that evaluated attention, psy-
chomotor speed, memory, speed of information processing, motor func-
tioning, intelligence, and depression. Subjects underwent sagittal T1-
weighted and axial and coronal T2-weighted spin echo MRIs.
Patients with carotid stenosis were found to have lower performance on
neuropsychologic tests with regard to attention, psychomotor speed, mem-
ory, and motor functioning. Results were independent of MRI lesions.
Cortical infarcts and white matter hyperintensities imaged by MRI were
equally distributed among people with and without carotid stenosis. Lacu-
nar infarcts were more frequent in the patients with carotid stenosis (P 
.03). No differences were found among patients with and without carotid
stenosis with regard to speed of information processing, word association, or
depression.
Comment: The impact of carotid stenosis on cognitive function con-
tinues to be debated. This article indicates that carotid stenosis is associated
with adverse performance in some aspects of neuropsychologic testing. We
do not know if it is the carotid stenosis itself or the conditions that lead to
carotid stenosis that actually affect neuropsychologic testing. This study
does not address whether correction of carotid stenosis results in improve-
ment of neuropscyhologic testing or slows degeneration of the neuropsy-
chologic functions potentially affected by with carotid stenosis.
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